SHOX2 and lung carcinoma: One biomarker under development is methylated SHOX2, which has shown promise in blood-based diagnosis of lung cancer (Kneip et al. 2011), and has more recently been investigated as marker of early response to treatment in lung cancer patients (Schmidt et al. 2015).